Clinical trials
2 active studies led by Emobot, of 3 in all
Source: ClinicalTrials.gov, Studies with Emobot (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
- 0Reports naming them
- 1Markets in public records
- 0Regions & countries
- 2Active trials they lead[1]
[1] ClinicalTrials.gov, Studies led by Emobot or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
Free public data on Emobot
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
See them on ClinicalTrials.gov (opens in a new tab)
Trials over time
Studies Emobot leads, by the year they started and their phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- No phase (devices, observational)
Source: ClinicalTrials.gov, Studies with Emobot or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets where public records show them
Markets we cover where free public records show Emobot: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
Topics
The topics of the markets Emobot is in.
From our blog
Stories on the topics Emobot works in.
Adaptogens: Ancient Herbs, Modern Market
170 WHO Member States report the use of traditional medicine. Adaptogens like ashwagandha, rhodiola and…
Read
Stress and Mood Supplements: Ashwagandha and Beyond
Depression and anxiety cost the world about US$1 trillion a year. Ashwagandha has some evidence for stress…
Read
Health Data Exchange: Why EDI Matters for Payers and Providers
Behind every insurance claim is a standard electronic message. The CAQH Index says $20 billion a year could…
Read